Beigene Ltd (NASDAQ:BGNE) has been assigned a consensus recommendation of “Buy” from the ten ratings firms that are presently covering the company, Marketbeat reports. Two research analysts have rated the stock with a sell recommendation, one has given a hold recommendation and seven have assigned a buy recommendation to the company. The average 12 month price target among analysts that have covered the stock in the last year is $187.00.

BGNE has been the subject of a number of research analyst reports. ValuEngine raised Beigene from a “hold” rating to a “buy” rating in a research note on Friday, June 1st. Credit Suisse Group initiated coverage on Beigene in a research note on Monday, May 14th. They issued an “outperform” rating for the company. Zacks Investment Research cut Beigene from a “hold” rating to a “sell” rating in a research note on Tuesday, July 10th. Piper Jaffray Companies set a $200.00 target price on Beigene and gave the company a “buy” rating in a research note on Monday, July 23rd. Finally, Maxim Group boosted their target price on Beigene from $200.00 to $225.00 and gave the company a “buy” rating in a research note on Friday, May 18th.

In other news, CMO Jane Huang sold 2,911 shares of the company’s stock in a transaction dated Tuesday, September 4th. The stock was sold at an average price of $174.60, for a total transaction of $508,260.60. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, Director Donald W. Glazer sold 2,000 shares of the company’s stock in a transaction dated Thursday, August 30th. The stock was sold at an average price of $179.00, for a total value of $358,000.00. Following the transaction, the director now directly owns 14,384 shares of the company’s stock, valued at $2,574,736. The disclosure for this sale can be found here. Over the last three months, insiders sold 16,679 shares of company stock valued at $2,808,018. Insiders own 14.10% of the company’s stock.

Several hedge funds have recently bought and sold shares of the company. Guggenheim Capital LLC boosted its position in shares of Beigene by 11.1% during the first quarter. Guggenheim Capital LLC now owns 5,583 shares of the company’s stock worth $938,000 after buying an additional 558 shares during the period. Tower Research Capital LLC TRC raised its holdings in Beigene by 5,558.3% during the second quarter. Tower Research Capital LLC TRC now owns 679 shares of the company’s stock worth $104,000 after acquiring an additional 667 shares in the last quarter. Comerica Bank raised its holdings in Beigene by 34.4% during the first quarter. Comerica Bank now owns 2,880 shares of the company’s stock worth $495,000 after acquiring an additional 737 shares in the last quarter. TD Asset Management Inc. raised its holdings in Beigene by 2.9% during the second quarter. TD Asset Management Inc. now owns 28,348 shares of the company’s stock worth $4,356,000 after acquiring an additional 800 shares in the last quarter. Finally, Rockefeller Capital Management L.P. bought a new stake in Beigene during the second quarter worth about $135,000. 77.87% of the stock is owned by institutional investors.

Shares of Beigene stock opened at $165.34 on Friday. The company has a quick ratio of 8.10, a current ratio of 8.14 and a debt-to-equity ratio of 0.16. Beigene has a 12 month low of $69.00 and a 12 month high of $220.10. The firm has a market cap of $8.79 billion, a P/E ratio of -74.14 and a beta of 0.62.

Beigene (NASDAQ:BGNE) last posted its earnings results on Thursday, August 9th. The company reported ($2.92) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($2.12) by ($0.80). Beigene had a negative net margin of 75.19% and a negative return on equity of 24.14%. The business had revenue of $52.80 million during the quarter, compared to analyst estimates of $22.53 million. During the same period in the previous year, the firm posted ($1.52) earnings per share. The firm’s revenue was up 5279999900.0% on a year-over-year basis. equities research analysts anticipate that Beigene will post -10.74 earnings per share for the current fiscal year.

About Beigene

BeiGene, Ltd., a clinical-stage biopharmaceutical company, develops and commercializes molecularly-targeted and immuno-oncology drugs for the treatment of cancer. Its commercial products include ABRAXANE, a solvent-free chemotherapy product for the treatment of breast, non-small cell lung, pancreatic, and gastric cancer; REVLIMID, an oral immunomodulatory drug for the treatment of multiple myeloma in combination with dexamethasone; and VIDAZA, a pyrimidine nucleoside analog for the treatment of intermediate-2 and high-risk myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia with 20% to 30% blasts and multi-lineage dysplasia.

Read More: Diversification Important in Investing

Analyst Recommendations for Beigene (NASDAQ:BGNE)

Receive News & Ratings for Beigene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Beigene and related companies with MarketBeat.com's FREE daily email newsletter.